New York:

纽约：

AstraZeneca

阿斯利康

Plc's experimental breast cancer pill delayed disease progression by over six months, according to data from a new study that is likely to capture investors' attention.

根据一项新研究的数据，Plc的实验性乳腺癌药物使疾病进展延迟了六个月以上，这一结果很可能引起投资者的关注。

Camizestrant

卡米泽司特朗

, in combination with other cancer medicines, helped patients with a specific type of breast cancer to live for a median of 16 months without their cancer progressing, compared with 9.2 months for those taking the current standard treatment.

，联合其他癌症药物，帮助特定类型的乳腺癌患者在癌症无进展的情况下中位生存期达到16个月，而接受当前标准治疗的患者为9.2个月。

Astra hopes the study data, presented at the American Society of Clinical Oncology's annual meeting in Chicago, will help establish a new treatment strategy for some breast cancer patients.

阿斯利康希望，在芝加哥举行的美国临床肿瘤学会年会上提交的这项研究数据，将有助于为某些乳腺癌患者建立新的治疗策略。

Camizestrant works as a

Camizestrant 的作用是

hormone therapy

激素治疗

to stop estrogen from attaching to cancer cells and helping them to grow.

阻止雌激素附着在癌细胞上并帮助其生长。

When other potential uses for camizestrant are taken into account, Astra believes the drug could bring in over $5 billion in annual sales. But analysts are more cautious as other similar drugs have failed, with Barclays estimating potential peak year sales at $3.6 billion.

考虑到卡米泽司特朗的其他潜在用途，阿斯利康认为该药物每年的销售额可能超过 50 亿美元。但分析师对此更加谨慎，因为其他类似药物均告失败，巴克莱银行估计其销售峰值可能达到 36 亿美元。

AstraZeneca

阿斯利康

has established itself as a

已经确立了自身作为

cancer drug

癌症药物

powerhouse under CEO Pascal Soriot, with medicines including Tagrisso and Imfinzi fueling growth.

在CEO帕斯卡尔·索里奥特的带领下，旗下拥有包括Tagrisso和Imfinzi在内的药物助力增长的强大企业。

Live Events

现场活动

(You can now subscribe to our

（您现在可以订阅我们的

Economic Times WhatsApp channel

经济时报 WhatsApp 频道

)

)

(You can now subscribe to our

（您现在可以订阅我们的

Economic Times WhatsApp channel

经济时报 WhatsApp 频道

)

)